An Open-label, Dose Escalation, Safety and Pharmacokinetics Phase 1 Study With AVE8062 Administered as a 30-minute Intravenous Infusion Every 3 Weeks in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2014
At a glance
- Drugs Ombrabulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 08 Sep 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 08 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Jul 2011 Planned end date changed from 1 Jun 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.